The 2017 MedTech Boston 40 Under 40 Healthcare Innovators

27. Omid Veiseh, Ph.D.
Co-Founder and Head of Innovation at Sigilon, Inc.
Dr. Omid Veiseh believes that cell-based therapies have the potential to revolutionize the treatment of many chronic and debilitating illnesses. That’s why he co-founded Siglion, a company that aims to use cell-based therapies to improve the management of type 1 diabetes.

Siglion is founded on seminal discoveries Veiseh made as a post-doctoral fellow in the laboratories of Bob Langer and Dan Anderson at Massachusetts Institute of Technology and Harvard Medical School.

“The project was aimed at developing biomaterials with improved biocompatibility that could enable cell transplantation for the treatment of type 1 diabetes,” says Veiseh of his work. “We were able to make significant strides towards this goal.”

After co-founding Siglion, Veiseh was offered a faculty position in the department of Bioengineering at Rice University. He postponed his start date so that he could join Sigilon full time to help build the company

“The most rewarding aspect of my job has been working with our world-class team at Sigilon,” says Veiseh of his job. “Everyone in the organization is motivated and passionate about making an impact. We work hard but we have a lot of fun doing what we do.”

In his free time, Veiseh enjoys spending time with his wife and two children.